< Ophthalmic Council 2008

Allergan

Go to www.allergan.com

Allergan is a PLATINUM level sponsor of the American Optometric Association.

Allergan

sponsors the following AOA programs:

As of February 2008

Optometry's Meeting™

Exclusive Friday Education Program
Specialty OD Education Course
Postcard Mailing Promotion
CLCS Student Research Award
Tripbuilder Mini-Map Promotion

Allergan offers and pursues innovative products to improve patient care

With nearly 60 years of successfully discovering and developing new therapeutic agents to help protect and preserve vision, Allergan's heritage offers eye care professionals and patients a broad range of products to treat a variety of eye conditions, including dry eye, glaucoma, and ocular surface diseases. As a result of dedicated R&D efforts and close relationships with eye care professionals, Allergan has established itself as a global leader in eye care.

"Optometrists play a central role in the provision of quality vision care," said Joseph J. Schultz, Allergan senior vice president, U.S. Eye Care. "At Allergan, we are proud to offer optometrists innovative therapeutics to provide their patients with a high level of care."

Robust product offerings and pipeline

Allergan offers optometrists a full continuum of care for their dry eye patients. Restasis® (cyclosporine ophthalmic emulsion) 0.05% is the only prescription eye drop available that is believed to treat an underlying cause of chronic dry eye by increasing tear production in cases where it may be reduced by inflammation. Allergan's dry eye portfolio also includes Optive™ Lubricant Eye Drops, a next-generation artificial tear with an advanced dual-action formula that provides long-lasting dry eye symptom relief, and the Refresh® brand line of artificial tears.

The newest ophthalmic product from Allergan is Combigan™ (brimonidine tartrate/ timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor approved by the U.S. Food and Drug Administration last year. Combigan™ is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. Allergan's robust glaucoma portfolio also includes Lumigan® (bimatoprost ophthalmic solution) 0.03% and Alphagan® P (brimonidine tartate ophthalmic solution) 0.1% and 0.15%. Allergan's other leading products include Zymar® (gatifloxacin ophthalmic solution) 0.3% and Acular® LS (ketorolac tromethamine ophthalmic solution) 0.4%.

Looking to the future, Allergan's robust R&D programs are focused on the discovery of advanced therapies for glaucoma, ocular surface diseases and back-of-the-eye diseases such as macular edema, diabetic retinopathy and age-related macular degeneration - diseases that unfortunately cause sight loss in thousands of patients each year and whose prevalence is increasing as the population ages.

Consistent Commitment to Optometry

Allergan works closely with third-party optometry groups, key opinion leaders and managed care organizations to stay abreast of optometrists' needs and remains committed to providing support for optometrists at all levels with a dedicated sales force, continuing education programs and educational initiatives for teaching institutions.

"Optometrists around the country have shared with me the issues that they find most important to their practices," said Paul King, product manager, Optometric Strategies. "In 2008, we will continue to focus on supporting educational programs that can help optometrists improve patient outcomes and build their practices."

Allergan supports the AOA and American Academy of Optometry meetings, Vision Expos (East and West) and regional and local section meetings.